Peking University's research team led by Liu Zhibo developed a targeted covalent radiopharmaceutical, showing excellent results in tumor treatment and diagnosis, with potential for wide application and cooperation.
Peking University's research team makes a significant breakthrough in radionuclide therapy with the development of targeted covalent radiopharmaceutical, showing excellent results in tumor treatment and diagnosis, with potential for wide application and cooperation.